Current Utilization of Mast Cell Stabilizers for Preemptive Treatment of NF1 Neurofibromas
Journal Title: Neuro – Open Journal - Year 2015, Vol 2, Issue 2
Abstract
The morbidity and mortality of Neurofibromatosis type I (NF1) are both largely related to the person’s neurofibroma burden. That burden can presently be minimized by mast cell stabilizers, with ketotifen as the one most frequently considered for NF1 patients in the published literature. Here, I review pertinent clinical and research publications to 1) document the rationale for using mast cell blockers in NF1, 2) consider the NF1 clinical impact of mast cell blockers, 3) document the relative safety and very modest expense of (at least some) mast cell blockers, and 4) suggest that the data are sufficiently robust to support the regular, if not routine use of mast cell blockers to treat NF1, particularly in children, while the NF1 neurofibroma burden is the least it will be. The rationale for these salutary results have been established by histopathology, Nf1+/- mouse models, a series of open-label and double-blind protocols, compelling case reports and a series of patients who have afforded their own self-determined mast cell stabilizer treatment (most often ketotifen). In addition, in the intervening 20-plus years since the first formal protocol publications, the positive treatment results have never been refuted or contradicted. The results of the mast-cell-stabilizing treatment are designed to keep the NF1 neurofibroma burden and its consequences at their minimums, in effect preempting NF1 neurofibroma initiation and progression as much as possible.
Authors and Affiliations
Vincent M. Riccardi
Keywords
Related Articles
- EP ID EP553088
- DOI 10.17140/NOJ2-115
- Views 115
- Downloads 0
Pulvinar Complex: Relay Center or Something More?
The pulvinar is a collection of thalamic nuclei which is often considered mainly with visual processing and attention. The unique thing about this thalamic brain area is that, in phylogeny, this area is considered to be...
Mobile Stroke Unit (MSU): The Future of Acute Stroke Treatment?
Time is the key factor in brain survivability in acute stroke treatment.1The therapeutic effects of intravenous recombinant tissue Plasminogen Activator (IV rtPA) are highly dependent on time.1-3 Stroke patients presenti...
Targeting Calcitonin Gene-Related Peptide and its Receptor by Monoclonal Antibody, New Developments in the Prevention of Migraine
Migraine is a chronic headache disorder with an unknown pathophysiology. Research in the past decade has shown that to be a brain disorder, a dismodulation of sensory processing affecting vascular tone and pain1-3 but si...
Neuromodulation in the Treatment of Migraine: Progress in Nerve Stimulation
Migraine is a type of primary headache disorder that can become chronic and disabling. The exact pathomechanism of migraine is not known very well and its treatment is also difficult in some cases. There are several medi...
Neurovascular Conflicts of Cerebellopontine Angle: A Review of the Literature
The pathology of the cistern of the cerebellopontine angle is primarily the disease of the nervous and vascular structures that it contains and of the meninges that line it. It appears by the Trigeminal Neuralgia (TN), H...